Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)

NCT05155293 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

413

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular (Wet) AMD

Interventions

DRUG: AVT06 (proposed aflibercept biosimilar)
DRUG: Eylea® (Aflibercept)

Sponsor

Alvotech Swiss AG